Bright Minds Biosciences Partners with Firefly Neuroscience
Ticker: DRUG · Form: 6-K · Filed: Oct 21, 2024 · CIK: 1827401
Sentiment: neutral
Topics: collaboration, news-release, biotech
TL;DR
Bright Minds & Firefly Neuroscience teaming up after BREAKTHROUGH study.
AI Summary
Bright Minds Biosciences Inc. announced on October 21, 2024, a collaboration with Firefly Neuroscience following the BREAKTHROUGH study. The specific details of the collaboration and its financial implications were not disclosed in this filing, which primarily serves as a notification of this event.
Why It Matters
This collaboration could lead to advancements in neuroscience research and potential new treatments, impacting the future development pipeline for both companies.
Risk Assessment
Risk Level: medium — The filing indicates a new collaboration, but lacks specific financial or operational details, making it difficult to assess the immediate impact or associated risks.
Key Players & Entities
- Bright Minds Biosciences Inc. (company) — Registrant
- Firefly Neuroscience (company) — Collaborating Party
- Ryan Cheung (person) — Chief Financial Officer
- October 21, 2024 (date) — Filing Date and News Release Date
FAQ
What is the nature of the collaboration between Bright Minds Biosciences and Firefly Neuroscience?
The filing states that the collaboration follows the BREAKTHROUGH study, but does not provide specific details on the terms or objectives of the collaboration.
When was the news release announcing this collaboration issued?
The news release (Exhibit 99.1) was dated October 21, 2024.
Who signed the 6-K report on behalf of Bright Minds Biosciences Inc.?
Ryan Cheung, Chief Financial Officer, signed the report.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is being submitted to report a news release (Exhibit 99.1) regarding the collaboration between Bright Minds Biosciences and Firefly Neuroscience.
Does Bright Minds Biosciences file annual reports under Form 20-F or 40-F?
Bright Minds Biosciences files annual reports under cover of Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 151 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-10-21 16:03:13
Filing Documents
- f6k20241021.htm (6-K) — 5KB
- ex991-20241021.htm (EX-99.1) — 14KB
- 0001183740-24-000084.txt ( ) — 19KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [ X ] Form 40-F [ ] SUBMITTED HEREWITH Exhibits 99.1 News Release dated October 21 , 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: October 21, 2024